These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7562908)

  • 41. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.
    Trumpp-Kallmeyer S; Rubin JR; Humblet C; Hamby JM; Showalter HD
    J Med Chem; 1998 May; 41(11):1752-63. PubMed ID: 9599227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
    Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ
    Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations.
    Zhang Y; Zhang K; Zhao M; Zhang L; Qin M; Guo S; Zhao Y; Gong P
    Bioorg Med Chem; 2015 Aug; 23(15):4591-4607. PubMed ID: 26122771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena.
    Kaspersen SJ; Sundby E; Charnock C; Hoff BH
    Bioorg Chem; 2012 Oct; 44():35-41. PubMed ID: 22832269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and preclinical evaluation of 5-methyl-N
    Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and activity of novel 5-substituted pyrrolo[2,3-d]pyrimidine analogues as pp60(c-Src) tyrosine kinase inhibitors.
    Olgen S; Isgör YG; Coban T
    Arch Pharm (Weinheim); 2008 Feb; 341(2):113-20. PubMed ID: 18214841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and biological evaluation of 6,7-disubstituted 4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors.
    Perner RJ; Lee CH; Jiang M; Gu YG; Didomenico S; Bayburt EK; Alexander KM; Kohlhaas KL; Jarvis MF; Kowaluk EL; Bhagwat SS
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2803-7. PubMed ID: 15911258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Thomas AP; Johnstone C; Stokes ES; Plé PA; Lohmann JJ; Ogilvie DJ; Dukes M; Wedge SR; Curwen JO; Kendrew J; Lambert-van der Brempt C
    J Med Chem; 1999 Dec; 42(26):5369-89. PubMed ID: 10639280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
    Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.
    Marchetti F; Cano C; Curtin NJ; Golding BT; Griffin RJ; Haggerty K; Newell DR; Parsons RJ; Payne SL; Wang LZ; Hardcastle IR
    Org Biomol Chem; 2010 May; 8(10):2397-407. PubMed ID: 20448898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells.
    Graness A; Hanke S; Boehmer FD; Presek P; Liebmann C
    Biochem J; 2000 Apr; 347(Pt 2):441-7. PubMed ID: 10749673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.
    Hubbard RD; Dickerson SH; Emerson HK; Griffin RJ; Reno MJ; Hornberger KR; Rusnak DW; Wood ER; Uehling DE; Waterson AG
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5738-40. PubMed ID: 18842405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
    Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
    Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.